FRAZIER LIFESCIENCES ACQUISITION CORPORATION

Communiqués Frazier Lifesciences Acquisition Corporation

Actions

NAMS

NL00150012L7

Cours en clôture Nasdaq Autres places de cotation 00:00:00 05/06/2024			Varia. 5j.	Varia. 1 janv.
19,22 ^EUR	+1,91%		+2,51%	+72,07%

21/05	NewAmsterdam Pharma Company N.V. présentera de nouvelles données cliniques et précliniques soulignant l'impact de l'Obicetrapib sur les principaux facteurs de risque des maladies cardiovasculaires lors de prochaines réunions médicales.	CI
16/05	Transcript : NewAmsterdam Pharma Company N.V. - Special Call

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	07/06	GL
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June	29/05	GL
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June	29/05	AQ
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings	21/05	GL
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings	21/05	AQ
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results	09/05	GL
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03/05	GL
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03/05	AQ
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024	02/05	GL
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024	02/05	AQ
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease	09/04	GL
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer	01/04	GL
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer	01/04	AQ
NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress	25/03	GL
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD	12/03	GL
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update	28/02	GL
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update	28/02	AQ
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March	26/02	GL
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March	26/02	AQ
NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants	14/02	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Frazier Lifesciences Acquisition Corporation

Actions

NAMS

NL00150012L7

Communiqués

Filtres